Shots:
Under the terms of the agreement, Sandoz received the exclusive right to commercialize and distribute Ogivri, the biosimilar version of Herceptin & Abevmy, the biosimilar version of Avastin, across Australia for the treatment of various cancer indications
Additionally, Sandoz AG will be held responsible to distribute Biocon’s biosimilar versions of trastuzumab and bevacizumab across Australia…
Shots:
Volker Wacheck sheds light on the recent approval of Lonsurf in combination with bevacizumab for patients with metastatic colorectal cancer
While sharing key insights from the pivotal P-III (SUNLIGHT) trial evaluating Lonsurf ± bevacizumab, Volker reveals that the combination drug is proven to prolong both OS and PFS along with QoL benefits and a…
Shots:
Philippe talked about the launch of the ABE-LIVER P-IIb study evaluating Ezurpimtrostat to treat hepatocarcinoma in combination with atezolizumab (an anti-PDL1) and bevacizumab (an antiangiogenic agent)
He also gave a brief on the study design and talked about the efficacy of Ezurpimtrostat with atezolizumab & bevacizumab, compared to SOC alone
The interview gives an…
“Get Informed, Get Screened, Get Vaccinated” – WHO
Introduction:
Cervical cancer is the 4th most common cancer among women and 7th most commonly occurring cancer overall. When a malignant growth or tumor occurs in the cells lining the walls of the cervix, it is called cervical cancer. The cervix is the narrow, lower part of the uterus…

